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The review system for human subjects research in the United States
has been widely criticized in recent years for requirements that
delay research without improving human subject protections. Any
major reformulation of regulations may take some time to imple-
ment. However, current regulations often allow for streamlined
ethics review that does not jeopardize—and may improve—
protections for research participants. The authors discuss under-
utilized options, including research that need not be classified as
human subjects research, categories of studies that can be ex-
empt from ethical review, studies that need only undergo expe-
dited review by 1 institutional review board (IRB) member, and
simplifying reviews of multicenter research by using the IRB of 1
institution. The authors speculate on multiple reasons for the
underuse of these mechanisms and exhort IRBs and researchers
to take advantage of these important opportunities to improve
the review process.
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The review system for human subjects research in theUnited States has been widely criticized in recent years.
Many commentators, particularly within the research com-
munity, complain of pointless bookkeeping requirements
that sap the morale of institutional review board (IRB)
members (1) and delay and obstruct lifesaving research (2).
Various diagnoses have been offered and correspond-
ing regulatory changes proposed to deal with what Fost
and Levine (3) call the “dysregulation of human subjects
research.” However, even if the regulations were to be sub-
stantially reformed, such change would take time to imple-
ment. In the meantime, ethics review could be streamlined
under the current regulations if institutions, IRBs, and
researchers adhered strictly to the definition of human sub-
jects research and used the available options for exemp-
tions, expedited review, and centralized review (4)—
options that remain underused in biomedical research.
According to Marjorie Speers, President of the Associ-
ation for the Accreditation of Human Research Protection
Programs, many institutions label activities as “human sub-
jects research” that do not fall under the federal definition
(5). Although much low-risk human subjects research is
exempt from review, some institutions insist on having all
their research reviewed by IRBs (6). A 1998 report (7)
found that for each category of exempt or expedited re-
search, 25% to 77% of U.S. IRBs “practice some form of
review that was more rigorous than specified by the regu-
lations.” There appear to be no data that contradict this
picture today.
These options may be underused for several reasons.
One key reason is probably lack of awareness, but another
is the fear of the consequences if the regulations are
deemed to be violated, which can include the complete
suspension of an institution’s federally funded research.
Our purpose here is to both inform and reassure.
HUMAN SUBJECTS RESEARCH
Institutional board review is legally required for re-
search conducted or funded by certain U.S. federal agen-
cies (8), regulated by the U.S. Food and Drug Administra-
tion, or carried out at institutions that have elected to
subject all their research to the Common Rule require-
ments. The regulations apply only to “human subjects re-
search,” in which investigators obtain data through some
“intervention or interaction” with living people or obtain
identifiable private information about them (9). Data from
people whose identities the investigator cannot “readily as-
certain” are not identifiable private information (10). For
much medical research, particularly that which uses clinical
data, researchers do not need to know the identity of the
participants and therefore need not conduct human sub-
jects research. For example, research that uses data from
medical records can be conducted in such a way that the
researchers cannot identify the person from whom the data
comes. Someone not involved in the research could remove
the identifiers from the data (such as the 18 specified
Health Insurance Portability and Accountability Act iden-
tifiers) (11) and agree never to disclose the code that links
those data to specific individuals. Researchers could even
set up a mechanism for receiving and removing the iden-
tifiers from future data without the regulations applying.
EXEMPTIONS AND EXPEDITED REVIEW
Even if a proposed research study is human subjects
research, it may fall into 1 of the 6 categories that are
exempt from ethical review. Two categories are of particu-
lar interest to biomedical researchers. Category 2 exempts
research that uses only educational tests, survey procedures,
interviews, or observation of public behavior, unless the
data recorded are both identifiable and potentially harmful
if disclosed. For example, the work of a researcher who
interviewed patients with HIV/AIDS about their medica-
tions and recorded their names would not be exempt under
category 2, because disclosure of the patients’ HIV/AIDS
status could harm them. However, if the researcher con-
ducted the interviews anonymously and never recorded the
patients’ names or other identifying information, the study
would probably be exempt.
Category 4 exempts research “involving the collection
or study of existing data, documents, records, pathological
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specimens, or diagnostic specimens,” if either the data
sources are publicly available or the recorded data do not
allow patient identification (9). For example, a retrospec-
tive chart review that examined the medications adminis-
tered to the most recent 50 patients seen at a hospital
emergency department for suspected cardiac infarction
would be exempt, provided the data were recorded without
patient identifiers. Decision charts for these exemptions
are available on the Web site of the Office for Human
Research Protections (www.hhs.gov/ohrp/humansubjects
/guidance/decisioncharts.htm).
If a protocol for conducting human subjects research is
not exempt, it may still be possible to expedite its review.
Initial and continuing review of certain categories of
minimal-risk research, such as that which involves only the
collection of blood samples or the noninvasive collection of
other biological specimens, can be expedited (12). Expe-
dited review is also permitted for minor changes in already
approved research. The same standards are followed as for
a full IRB review, but the review is done by just the chair-
person or by designated experienced IRB members. Be-
cause expedited review can be conducted on an ongoing
basis, its use should speed up the review process and reduce
the time that the convened IRB spends reviewing minimal-
risk research. The sparse data available indicate that for
some institutions, expedited reviews save little money (13)
and no time (14), which suggests that some IRB proce-
dures also need streamlining.
MULTICENTER RESEARCH
Since the regulations were established, the number of
collaborative studies that take place at multiple institutions
has greatly increased. Because responsibility for ethical re-
view rests with institutions, multicenter research frequently
results in the IRB of each institution reviewing the same
protocol (15). This both duplicates work and increases the
time and resources spent getting research projects ap-
proved, as different IRBs mandate different (often minor)
changes to consent documents and researchers go back and
forth between them.
Again, regulatory resources for addressing this problem
already exist. According to the Common Rule (9), when a
research project involves more than 1 institution, “an in-
stitution participating in a cooperative project may enter
into a joint review arrangement, rely upon the review of
another qualified IRB, or make similar arrangements for
avoiding duplication of effort.” This arrangement is under-
used mainly because of institutional reluctance to cede con-
trol and underlying liability concerns. The Office for Hu-
man Research Protections recently published a request for
public comments on an amendment to the regulations that
would allow it to hold IRBs and the organizations that
operate them directly responsible for meeting some regula-
tory requirements, rather than always enforcing compli-
ance through the institutions engaged in the research (16).
For example, if an independent IRB reviewed a particular
study and incorrectly approved it by using expedited re-
view when the study should have undergone review by the
convened IRB, any compliance action would fault the
IRB—not the institution that hired it to review the study.
The amendment’s goal is to encourage more institutions to
rely on review by an external IRB by reducing their liability
concerns.
One existing “joint review” arrangement is the Central
Institutional Review Board (CIRB) Initiative (www.ncicirb
.org), sponsored by the National Cancer Institute, which
covers certain National Cancer Institute–sponsored multi-
center adult and pediatric cancer studies. For studies in the
initiative, the CIRB performs a single review of the proto-
col. Local IRBs may then defer to the CIRB and perform
only a “facilitated review” of ethical issues that arise be-
cause of the local context. The CIRB generally performs
the continuing reviews, amendment reviews, and reviews
of serious adverse events for the protocol.
ETHICAL CONCERNS
Medical research pursues the ethically important goal
of developing interventions to improve human health. It
does so under the constraint of another goal—protecting
research participants. Measures that speed up the ethics
review process clearly help with the first goal by reducing
the time that it takes to develop health care interventions
and allowing resources that would otherwise be taken up
by ethical review to be directed toward beneficial research.
Expending excessive resources on reviewing studies that
pose minimal risks or replicating review by other IRBs is
ethically troubling.
One concern, however, might be that speeding up eth-
ical review would compromise the welfare of the people it
is designed to protect. However, following these measures
is unlikely to reduce human subject protections. The cate-
gories of research that are exempt or eligible for expedited
review are unlikely to include highly unethical studies. For
example, studies in these categories almost always pose no
more than minimal risk to participants, which should ame-
liorate concerns about participant harm. Thus, the absolute
probability of increased use of these measures leading to
more unethical research is low.
In addition, IRBs always have constraints on their
time and resources, and any time they spend reviewing one
protocol takes away time from reviewing others. Institu-
tional review boards should prioritize their time to focus
on protocols that are more likely to generate ethical issues
but need a way to determine whether a study will raise
ethical issues without actually reviewing the full protocol.
The regulatory measures we have detailed identify catego-
ries of research that are unlikely to be ethically problem-
atic. Using them therefore frees up resources for reviewing
riskier research.
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ACTION
This article has 2 main goals: to inform biomedical
researchers about the measures through which the ethical
review of low-risk and multicenter research could be made
more efficient under the existing regulations, and to extol
the virtues of these measures to researchers, IRBs, and in-
stitutional officials. These measures may not only allow
valuable research to be carried out more rapidly but also
reduce the cost of protocol review and allow IRBs to focus
on research that is more likely to be ethically challenging.
Researchers cannot act alone. Institutional review
board offices and the officials who oversee them must be
willing to prioritize time and resources by allowing ex-
emptions and developing efficient procedures to expe-
dite reviews. In addition, the institutions that host re-
search must be willing to trust the ethical review systems
at other institutions—and that trust must be built. Finally,
regulatory bodies need to reassure the research community
that their primary concerns lie not with meeting bureau-
cratic requirements but with genuinely protecting human
participants. That message will help encourage institutions
to appropriately streamline their policies and procedures by
minimizing concerns about being subject to inappropriate
regulatory responses.
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